Testosterone Therapy for Men: The Full Picture on Testing, Dosing and Real Risks
Matt Kaeberlein and Dr. Kevin White unpack how men's testosterone declines slowly with age, why total testosterone alone tells you almost nothing, and why the full panel — free testosterone, SHBG, albumin, LH and FSH — is what actually explains the picture. They discuss primary versus secondary patterns, low-dose twice-weekly protocols, delivery formats, and why most of the fear around hormone therapy comes from doses far above the physiological range.
Overview
This conversation is a practical walk-through of male hormone health with Dr. Kevin White, a concierge physician in Oklahoma, hosted by Matt Kaeberlein. They start with prevalence: unlike the abrupt change women experience, men see a slow steady decline that is easy to push through and ignore. White suggests men start looking at their markers around 40 — earlier if fatigue, poor stress tolerance or disrupted sleep show up.
The panel he describes goes well beyond total testosterone: free testosterone as the active fraction, SHBG and albumin as the binding proteins, plus LH and FSH to read what the brain is signalling, alongside a CBC, thyroid and insulin-resistance markers. That distinction separates primary patterns (the testicles are not producing) from secondary ones (the pituitary signal is weak), and the second group is often the one where sleep, stress, alcohol and training make a real difference before anything else is considered.
On protocols, White favours small twice-weekly injections over large infrequent doses or pellets, because steady levels avoid the peaks and troughs some men feel strongly. He walks through the trade-offs of oral, topical and pellet formats, including transference risk with creams. The risk conversation gets the most airtime: hair loss via DHT is real but manageable, mood changes and polycythemia track with excessive dosing, and he argues the prostate cancer fear is largely inherited from decades-old thinking and from bodybuilding-era abuse rather than physiological use.
Both agree the fertility trade-off is the genuinely permanent one — exogenous testosterone shuts down the feedback loop, which is why younger men are steered toward clomiphene first. They close on scale: White estimates 80% or more of men would at least benefit from having this addressed, while stressing follow-up labs every 8 to 12 weeks and choosing a provider who actually measures.
Key quotes
5It could just be such a slow steady decline. If you're interested in the longevity space, it lowers all-cause mortality if treated the appropriate way.
You're getting a tiny tiny fraction of the whole picture. And if you're basing your treatment off that, you're not really treating the issue.
You have the exogenous testosterone and then the LH bottoms out, and after a while you can't recover from that.
So much of the literature suggesting negative health consequences comes from super-physiological doses often used for performance enhancement.
It's just one big tool in the toolkit, but it's one of many things.
Key ideas
9The decline is slow, which is exactly why it gets missed
Men experience a gradual drop rather than a sharp transition, so there is rarely an acute moment that forces attention. Both hosts admit that the cultural habit of pushing through delays even routine screening.
Around 40 is the natural checkpoint
White suggests men look at their hormone markers around 40, when broader biomarker checks make sense anyway. Persistent fatigue, poor stress tolerance or disrupted sleep can justify looking in the mid-to-late 30s.
Free testosterone is the fraction that matters
Most circulating testosterone is bound to SHBG and albumin, leaving a small free fraction as the active form. Two men with identical totals can sit in very different places once binding proteins are accounted for.
LH and FSH read the signal from the brain
Luteinising hormone and follicle-stimulating hormone are produced by the anterior pituitary and tell the testicles what to do. Their pattern reveals whether a low reading originates centrally or in production itself.
Primary and secondary point to different paths
In primary patterns LH can be normal or elevated while production still falls short. In secondary patterns the signal itself is weak, and White notes this group often responds to lifestyle work on sleep, stress and alcohol.
Symptoms belong in the assessment, not just numbers
Reference ranges are extremely wide, so White reads labs alongside fatigue, muscle and bone status, libido and stress tolerance. A man with a lowish reading and no symptoms is not automatically a candidate.
Exogenous testosterone closes the feedback loop
Once outside testosterone is supplied, LH and FSH can bottom out and may not recover, affecting both natural production and sperm. This is why younger men are evaluated carefully and often directed toward clomiphene first.
Steady beats spiky
White's preference is small doses twice weekly rather than a large hit every week or two, which produces a spike and a long tail. Level readings track better with how men actually feel across the week.
Most of the risk story is a dose story
Hair loss via DHT, mood changes and polycythemia cluster around excessive levels rather than physiological ones. White reports patients arriving from other clinics with readings several times the normal range.
Practical takeaways
7- 1
Ask for the full panel, not one number 7:30
Total testosterone on its own leaves out the binding picture entirely. The conversation is far more useful when free testosterone, SHBG, albumin, LH and FSH are on the same page.
- 2
Put hormones in context with the rest of your labs 12:30
White pairs the hormone panel with a CBC, thyroid markers and insulin-resistance measures. Metabolic health and hormone health move together, so reading one without the other is misleading.
- 3
Work the lifestyle levers first 22:00
Sleep quality, stress load, alcohol, resistance training and nutrient-dense food all influence where levels land. In younger men especially, addressing these can shift the picture before anything else is considered.
- 4
Think about fertility before, not after 34:00
The shutdown of natural production and sperm output can be lasting. Anyone who might want children later should have that conversation at the evaluation stage rather than years down the road.
- 5
Know the trade-offs of each format 40:00
Injections allow fine control and clear lab tracking; creams are convenient but carry transference risk to a partner and may not show up clearly in blood work; pellets are convenient but produce a high then a fade.
- 6
Re-check at 8 to 12 weeks, every time 51:00
White treats follow-up labs as non-negotiable to confirm levels stay in physiological range. Starting low and adjusting upward is his stated default rather than opening high.
- 7
Choose a provider who measures 57:00
Both hosts flag the gap between clinics that hand out prescriptions after a short call and those that evaluate, monitor and follow PSA. The quality of the monitoring is what separates the two.
Topics & chapters
15How common is this really?
The conversation opens on prevalence and why men rarely act on a slow decline. White's view is that it is worth every man checking.
When to start looking
Around 40 as a general checkpoint, earlier when fatigue, stress intolerance or poor sleep show up. Both hosts note they wish they had baseline data from their thirties.
The biomarker panel
Total and free testosterone, SHBG and albumin, plus CBC, thyroid and insulin-resistance markers. Free testosterone is typically calculated rather than measured directly.
LH, FSH and the pituitary signal
How luteinising and follicle-stimulating hormone drive production and sperm output. Their levels reveal whether the issue sits centrally or in the testicles.
Primary versus secondary patterns
White separates failure of production from failure of signalling, and explains why root cause matters more than the headline number.
Wide reference ranges and symptoms
Why the same reading means different things for different men, and the symptom list White works through — fatigue, muscle and bone loss, libido, stress tolerance, even dry eyes.
Clomiphene and preserving fertility
How clomiphene acts at the hypothalamus to raise LH and FSH, and why it is often the first route for younger men with a secondary pattern.
The feedback loop and its permanence
Starting outside testosterone young without proper evaluation can end natural production and sperm output for good. The plan is discussed before anything begins.
Dosing rhythm
Small twice-weekly injections rather than large infrequent doses, and why steadier levels suit most men better than peaks and troughs.
Injections, oral, topical and pellets
The practical trade-offs of each format, including liver concerns with older oral versions, transference risk with creams, and the three-month cycle of pellets.
Hair loss, mood and cancer fears
DHT and the five-alpha-reductase pathway, topical options, and why White views the prostate cancer worry as largely inherited from super-physiological use and decades-old thinking.
Polycythemia and monitoring
Haemoglobin and haematocrit can rise with large infrequent dosing, with therapeutic phlebotomy as the response. White says it rarely comes up at low twice-weekly dosing.
What the benefits look like
Lean mass and bone density, fall risk, libido, sleep quality, stress tolerance, insulin resistance and lipids — with the caveat that health span, not lifespan, is the clearer claim.
How many men are we talking about?
White estimates 80% or more would benefit from having this addressed in some form, and both note how small the fraction receiving careful monitoring actually is.
Closing thoughts
Hormone care as one big lever among diet, training, sleep and relationships — with the repeated reminder to re-check at 8 to 12 weeks.